Table 1.
Demographic and patients characteristics
| Control group (N = 299) |
Intervention group (N = 177) |
Differences (P-value) |
|
|---|---|---|---|
| Male (n/%) | 181 (61%) | 115 (65%) | 0.20 |
| Age | 64 ± 14 | 63 ± 14 | 0.64 |
| APACHE-II score | 20 ± 7 | 19 ± 6 | 0.06 |
| Urgent admission (%) | 261 (87%) | 152 (86%) | 0.52 |
| Sedation level (RASS, median (IQR)) - RASS screening compliance (%) |
-1 (-3 to 0) 93.3 ± 1.2 |
-1 (-3 to 0) 94.5 ± 0.9 |
0.84 |
| Haloperidol administering | |||
| - Number of treated patients (%) | 225 (75.3%) | 177 (100%) | <0.0001 |
| - Number of treated days | 5 (2 to 12) | 5 (3 to 11)* | 0.23 |
| - Dosage (mg per day) median ((IQR)) | 6 (3 to 10) | 2 (2 to 3) | <0.0001 |
| Sepsis (N/%) | 64 (21%) | 53 (30%) | 0.02 |
| Admission specialism (N/%): | |||
| - Surgical | 75 (25%) | 33 (19%) | 0.18 |
| - Medical | 143 (48%) | 106 (60%) | 0.12 |
| - Trauma | 32 (11%) | 18 (10%) | 0.27 |
| - Neurology/neurosurgical | 49 (16%) | 20 (11%) | 0.36 |
| PRE-DELIRIC score | 73 ± 22 | 75 ± 19 | 0.50 |
| Other risk | |||
| - Alcohol abuse | 41 (14%) | 20 (11%) | 0.37 |
| - Dementia | 5 (2%) | 2 (1%) |
* Including prophylactic days of treatment. Data are presented as mean ± standard deviation unless mentioned otherwise.